Brief: Radiopharm Theranostics Achieves Primary Endpoint In 92% Of Patients At Interim Analysis Of Rad 101 Phase 2B Imaging Trial In Brain Metastases
15/12/2025 12:14
Dec 15 (Reuters) - Radiopharm Theranostics Ltd RAD.AX: RADIOPHARM THERANOSTICS LTD: ACHIEVES PRIMARY ENDPOINT IN 92% OF PATIENTS AT INTERIM ANALYSIS OF RAD 101 PHASE 2B IMAGING TRIAL IN BRAIN METASTASES Source text: ID:nGNX3b9141 Further company coverage: RAD.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%